Seikagaku Keeps Momentum in International Markets

Seikagaku reported FY3Q21 orthopedic sales of ¥3,555 million ($34.1 million), +4.1% vs. FY3Q20.

The market recovery in Japan and abroad has helped the company increase sales volume. In Japan, Seikagaku is still contending with drug price reductions and the adverse side effects caused by its new JOYCLU knee osteoarthritis treatment.

The...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0